- Home
- IPSC vs RFAI Comparison
IPSC vs RFAI Comparison
Compare IPSC & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- RFAI
- Stock Information
- Founded
- IPSC 2019
- RFAI 2024
- Country
- IPSC United States
- RFAI Singapore
- Employees
- IPSC N/A
- RFAI N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- RFAI
- Sector
- IPSC Health Care
- RFAI
- Exchange
- IPSC Nasdaq
- RFAI NYSE
- Market Cap
- IPSC 149.1M
- RFAI 153.1M
- IPO Year
- IPSC 2021
- RFAI 2024
- Fundamental
- Price
- IPSC $1.21
- RFAI $10.18
- Analyst Decision
- IPSC Strong Buy
- RFAI
- Analyst Count
- IPSC 4
- RFAI 0
- Target Price
- IPSC $13.00
- RFAI N/A
- AVG Volume (30 Days)
- IPSC 497.3K
- RFAI 12.9K
- Earning Date
- IPSC 11-05-2024
- RFAI 01-01-0001
- Dividend Yield
- IPSC N/A
- RFAI N/A
- EPS Growth
- IPSC N/A
- RFAI N/A
- EPS
- IPSC N/A
- RFAI N/A
- Revenue
- IPSC $2,684,000.00
- RFAI N/A
- Revenue This Year
- IPSC $244.52
- RFAI N/A
- Revenue Next Year
- IPSC $27.73
- RFAI N/A
- P/E Ratio
- IPSC N/A
- RFAI N/A
- Revenue Growth
- IPSC 7.88
- RFAI N/A
- 52 Week Low
- IPSC $1.14
- RFAI $10.00
- 52 Week High
- IPSC $5.51
- RFAI $10.27
- Technical
- Relative Strength Index (RSI)
- IPSC 38.14
- RFAI N/A
- Support Level
- IPSC $1.20
- RFAI N/A
- Resistance Level
- IPSC $1.29
- RFAI N/A
- Average True Range (ATR)
- IPSC 0.12
- RFAI 0.00
- MACD
- IPSC -0.01
- RFAI 0.00
- Stochastic Oscillator
- IPSC 2.71
- RFAI 0.00
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.